





thyrotropin	 (TSH),	 the	pituitary	hormone	 that	 fluctuates	according	 to	 the	circulating	 levels	of	
thyroid	hormones	-	thyroxine	(T4)	and	its	biologically	active	metabolite,	triiodothyronine	(T3).	
High	serum	TSH	levels	indicate	that	the	thyroid	secretion	is	insufficient,	establishing	the	diagno-



















male	euthyroid	patients	 studied	before	and	one	year	after	 total	 thyroidectomy	 revealed	 that	
while	on	LT4	therapy	patients	exhibited	an	increase	in	serum	LDL-cholesterol	levels	of	6	mg/dl,	
despite	normalization	of	 serum	TSH	 (5).	A	 similar	 study	of	 1,092	 LT4-treated	 female	patients	
also	revealed	elevation	of	about	15	mg/dl	in	total	cholesterol	levels	two	years	after	surgery	(4).	
In	 fact,	 a	 meta-analysis	 of	 65	 studies	 that	 compared	 1,878	 LT4-treated	 patients	 to	 14,493	














As	 in	many	 tissues,	T3	signaling	 in	 the	 liver	 is	defined	by	 the	 levels	of	circulating	T3.	There	 is	




















patients	exhibit	mildly	elevated	 serum	TSH	while	keeping	 	 serum	T4	and	T3	 levels	within	 the	
population	 reference	 range.	Whereas	 such	patients	do	exhibit	 alterations	 in	 lipid	profile,	 it	 is	
not	clear	that	treatment	with	LT4	results	in	measurable	benefits	.	Indeed,	it	is	only	in	the	more	
severe	end	of	SCH	that	clear	benefits	of	correcting	SCH	with	regard	to	cardiovascular	risk	fac-
tors	are	seen	and	only	in	younger	and	middle-aged	individuals	(15).			Persistent	subclinical	hy-
pothyroidism	due	to	ongoing	thyroid	inflammation	or	other	intrinsic	thyroid	disease,	will	result	
in	preservation	of	T3	levels	and	T3:T4	ratio	which	is	not	observed	in	individuals	on	LT4.	
 
	
Conclusion:		
This	summary	highlights	that	whilst	abnormal	lipid	profiles	and	hypothyroidism	often	promote	
screening	for	the	other	condition,	it	is	important	to	realise	that	individuals	on	LT4	are	also	at	
increased	risk	of	developing	hyperlipidemia.	Therefore	the	screening	for	an	abnormal	lipid	pro-
file	should	continue	in	hypothyroid	individuals	even	after	normalization	of	TSH.	This	summary	
also	raises	a	broader	issue;	lipid	metabolism	is	something	which	we	can	readily	measure	with	
simple	blood	tests	it	is	easy	to	identify	as	a	problem.	The	effects	of	lower	T3	availability	and	
subsequent	gene	expression	in	other	tissues	such	as	the	brain,	may	affect	outcomes	such	as	
fatigue	and	mood	which	are	less	easily	measured	but	of	perhaps	greater	importance	to	the	pa-
tient.														
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